Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the commercial manufacturing of ADCs with the launch of a cutting-edge payload manufacturing workshop at its Le Mans site (France). This expansion, which is part of the France 2030 program, builds on Axplora’s proven commercial track record, supplying 40% of the world’s marketed ADCs, and 50% of FDA-approved ADCs.
The new state-of-the-art facility reinforces Axplora’s commitment to deliver high-quality clinical and commercial-scale solutions for ADC development and manufacturing. Axplora continues to partner with leading innovative pharmaceutical companies developing the next generation of targeted therapies in oncology, benefitting thousands of patients worldwide.
“This expansion is a bold step forward in our mission to support clients at every stage of ADC development and manufacturing,” stated Arul Ramadurai, Chief Commercial Officer. “By combining state-of-the-art payload manufacturing with our proven expertise in purification and bioconjugation, we’re enabling pharmaceutical innovators to accelerate drug development and deliver transformative treatments to patients faster.”
“With this investment, Axplora is strengthening its position as a global leader in the development and manufacturing of antibody-drug conjugates,” said Rachel de Luca, Site Director, Le Mans. “The addition of this new payload manufacturing asset demonstrates our dedication to equipping clients with the cutting-edge tools and capabilities needed to develop the next generation of life-saving therapies.”
Comments powered by CComment